Proteomic analysis of mitochondria reveals a metabolic switch from fatty acid oxidation to glycolysis in the failing heart

Science in China, Series C: Life Sciences

Volumn 52, Issue 11, 2009, Pages 1003-1010

  Wang, Jun ^a,b   Bai, Ling ^a,b   Li, Jing ^c   Sun, Chao Feng ^a,b   Zhao, Jin ^a   Cui, Chang Cong ^a,b   Han, Ke ^a,b   Liu, Yu ^a,b   Zhuo, Xiao Zhen ^a,b   Wang, Ting Zhong ^a,b   Liu, Ping ^a,b   Fan, Fen Ling ^a,b   Guan, You Fei ^c   Ma, Ai Qun ^a,b  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c Peking University Health Science Center   (China)

Author keywords

Energy metabolism; Heart failure; Mitochondria; Proteome; Two dimensional electrophoresis

Indexed keywords

FATTY ACID; MITOCHONDRIAL PROTEIN; PROTEOME;

ANIMAL; ARTICLE; CHEMISTRY; ENERGY METABOLISM; GLYCOLYSIS; HEART FAILURE; HEART MITOCHONDRION; HEART MUSCLE; HUMAN; MALE; MASS SPECTROMETRY; METABOLISM; MOLECULAR GENETICS; ORGAN SIZE; OXIDATION REDUCTION REACTION; PATHOLOGY; PHYSIOLOGY; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; ENERGY METABOLISM; FATTY ACIDS; GLYCOLYSIS; HEART FAILURE; HUMANS; MALE; MITOCHONDRIA, HEART; MITOCHONDRIAL PROTEINS; MOLECULAR SEQUENCE DATA; MYOCARDIUM; ORGAN SIZE; OXIDATION-REDUCTION; PROTEOME; RATS; RATS, SPRAGUE-DAWLEY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

RATTUS;

EID: 73249130842     PISSN: 10069305     EISSN: 18622798     Source Type: Journal    
DOI: 10.1007/s11427-009-0140-2     Document Type: Article

References (36)

1. Braunwald E. Shattuck lecture-cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med, 1997, 337: 1360-1369.
2. Kannel W B. Incidence and epidemiology of heart failure. Heart Fail Rev, 2000, 5: 167-173.
3. Drexler H. Heart failure: pathophysiology, molecular biology, and clinical management. N Engl J Med, 2000, 342: 2005-2006.
4. Murray A J, Edwards L M, Clarke K. Mitochondria and heart failure. Curr Opin Clin Nutr Metab Care, 2007, 10: 704-711.
5. Tsutsui H. Mitochondrial oxidative stress and heart failure. Intern Med, 2006, 45: 809-813.
6. Tsutsui H, Kinugawa S, Matsushima S. Mitochondrial oxidative stress and dysfunction in myocardial remodelling. Cardiovasc Res, 2009, 81: 449-456.
7. Hardy C J, Weiss R G, Bottomley P A, et al. Altered myocardial high-energy phosphate metabolites in patients with dilated cardiomyopathy. Am Heart J, 1991, 122 (3 Pt 1): 795-801.
8. Neubauer S, Horn M, Naumann A, et al. Impairment of energy metabolism in intact residual myocardium of rat hearts with chronic myocardial infarction. J Clin Invest, 1995, 95: 1092-1100.
9. Graham B H, Waymire K G, Cottrell B, et al. A mouse model for mitochondrial myopathy and cardiomyopathy resulting from a deficiency in the heart/muscle isoform of the adenine nucleotide translocator. Nat Genet, 1997, 16: 226-234.
10. Wang J, Wilhelmsson H, Graff C, et al. Dilated cardiomyopathy and atrioventricular conduction blocks induced by heart-specific inactivation of mitochondrial DNA gene expression. Nat Genet, 1999, 21: 133-137.
11. Li Y, Huang T T, Carlson E J, et al. Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase. Nat Genet, 1995, 11: 376-381.
12. Johnson D T, Harris R A, French S, et al. Tissue heterogeneity of the mammalian mitochondrial proteome. Am J Physiol Cell Physiol, 2007, 292: C689-697.
13. Taylor S W, Fahy E, Zhang B, et al. Characterization of the human heart mitochondrial proteome. Nat Biotechnol, 2003, 21: 281-286.
14. Fountoulakis M, Soumaka E, Rapti K, et al. Alterations in the heart mitochondrial proteome in a desmin null heart failure model. J Mol Cell Cardiol, 2005, 38: 461-474.
15. Sakakibara Y, Nishimura K, Tambara K, et al. Prevascularization with gelatin microspheres containing basic fibroblast growth factor enhances the benefits of cardiomyocyte transplantation. J Thorac Cardiovasc Surg, 2002, 124: 50-56.
16. Nishina T, Nishimura K, Yuasa S, et al. Initial effects of the left ventricular repair by plication may not last long in a rat ischemic cardiomyopathy model. Circulation, 2001, 104 (12 Suppl 1): I241-245.
17. Santos A A, Helber I, Flumignan R L, et al. Doppler echocardiographic predictors of mortality in female rats after myocardial infarction. J Card Fail, 2009, 15: 163-168.
18. Dent M R, Singal T, Dhalla N S, et al. Expression of phospholipase D isozymes in scar and viable tissue in congestive heart failure due to myocardial infarction. J Cell Mol Med, 2004, 8: 526-536.
19. Mela L, Seitz S. Isolation of mitochondria with emphasis on heart mitochondria from small amounts of tissue. Methods Enzymol, 1979, 55: 39-46.
20. Gorg A, Weiss W, Dunn M J. Current two-dimensional electrophoresis technology for proteomics. Proteomics, 2004, 4: 3665-3685.
21. Jiang L, Lindpaintner K, Li H F, et al. Proteomic analysis of the cerebrospinal fluid of patients with schizophrenia. Amino Acids, 2003, 25: 49-57.
22. Xun M, Zhao S H, Cao C X, et al. Proteomic analysis of HuH-7 cells harboring in vitro-transcribed full-length hepatitis C virus 1b RNA. Acta Pharmacol Sin, 2008, 29: 720-727.
23. Krzeminski T F, Nozynski J K, Grzyb J, et al. Wide-spread myocardial remodeling after acute myocardial infarction in rat. Features for heart failure progression. Vascul Pharmacol, 2008, 48(2-3): 100-108.
24. Bing R J, Siegel A, Ungar I, et al. Metabolism of the human heart. II. Studies on fat, ketone and amino acid metabolism. Am J Med, 1954, 16: 504-515.
25. Carlsten A, Hallgren B, Jagenburg R, et al. Myocardial metabolism of glucose, lactic acid, amino acids and fatty acids in healthy human individuals at rest and at different work loads. Scand J Clin Lab Invest, 1961, 13: 418-428.
26. Wisneski J A, Gertz E W, Neese R A, et al. Myocardial metabolism of free fatty acids. Studies with 14C-labeled substrates in humans. J Clin Invest, 1987, 79: 359-366.
27. Lopaschuk G D, Collins-Nakai R L, Itoi T. Developmental changes in energy substrate use by the heart. Cardiovasc Res, 1992, 26: 1172-1180.
28. Schwer B, Bunkenborg J, Verdin R O, et al. Reversible lysine acetylation controls the activity of the mitochondrial enzyme acetyl-CoA synthetase 2. Proc Natl Acad Sci USA, 2006, 103: 10224-10229.
29. Thorpe C, Kim J J. Structure and mechanism of action of the acyl-CoA dehydrogenases. FASEB J, 1995, 9: 718-725.
30. Opie L H, Sack M N. Metabolic plasticity and the promotion of cardiac protection in ischemia and ischemic preconditioning. J Mol Cell Cardiol, 2002, 34: 1077-1089.
31. Orchard C. The effect of acidosis on excitation-contraction coupling in isolated ferret heart muscle. Mol Cell Biochem, 1989, 89: 169-173.
32. Chiu H C, Kovacs A, Ford D A, et al. A novel mouse model of lipotoxic cardiomyopathy. J Clin Invest, 2001, 107: 813-822.
33. Taegtmeyer H. Cardiac metabolism as a target for the treatment of heart failure. Circulation, 2004, 110: 894-896.
34. Nikolaidis L A, Elahi D, Hentosz T, et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation, 2004, 110: 955-961.
35. Hasenfuss G, Maier L S, Hermann H P, et al. Influence of pyruvate on contractile performance and Ca(2+) cycling in isolated failing human myocardium. Circulation, 2002, 105: 194-199.
36. Zhong P, Wang W Y, Zhou X F, et al. Effects of trimetazidine on myocardial metabolism evaluated by PET-CT in patients with ischemic cardiomyopathy. Zhonghua Xin Xue Guan Bing Za Zhi, 2008, 36: 36-39.